Highlights d FGL1 is a major ligand of LAG-3 that mediates T cell suppression d FGL1 is normally released by the liver in low levels but by cancer in high levels d Blockade of the FGL1-LAG-3 interaction potentiates antitumor immunity
INTRODUCTION
Lymphocyte-activation gene 3 (LAG-3, CD223) is a transmembrane protein primarily found on activated T cells (Anderson et al., 2016; Andrews et al., 2017; Triebel et al., 1990) . LAG-3 protein consists of four extracellular immunoglobulin (Ig)-like domains (D1-D4) with high homology to CD4 (Triebel et al., 1990) . LAG-3 expression can be upregulated by interleukin (IL)-2 and IL-12 on activated T cells (Annunziato et al., 1996 (Annunziato et al., , 1997 Bruniquel et al., 1998) , where it mainly functions as a receptor that delivers inhibitory signals (Huard et al., 1994 (Huard et al., , 1996 Workman et al., 2002a) . LAG-3 negatively regulates the proliferation, activation, effector function, and homeostasis of both CD8 + and CD4 + T cells, as shown in LAG-3 knockout mice and antibody studies (Huard et al., 1994; Workman et al., 2002a Workman et al., , 2002b Workman et al., , 2004 Vignali, 2003, 2005) . LAG-3 may represent an ''exhaustion'' marker for CD8 + T cells similar to PD-1 in response to repetitive antigen stimulation in chronic viral infections or cancers (Blackburn et al., 2009; Chihara et al., 2018; Grosso et al., 2007 Grosso et al., , 2009 Matsuzaki et al., 2010; Williams et al., 2017) . Additionally, LAG-3 is also constitutively expressed on a subset of regulatory T cells and contributes to their suppressive function (Camisaschi et al., 2010; Gagliani et al., 2013; Huang et al., 2004) . Currently, monoclonal antibodies (mAbs) that block the interaction of LAG-3 with its canonical ligand, MHC-II, are being evaluated for their antitumor activity in clinical trials (Anderson et al., 2016; Rotte et al., 2018) .
The major ligand that mediates the immune suppressive functions of LAG-3, however, remains controversial. Initial studies by Baixeras et al. (1992) showed an interaction between MHC-II and LAG-3 via a cell-cell adhesion assay, which was further extended by studies indicating LAG-3 fusion protein binding to MHC-II + B cell lines (Huard et al., 1995 (Huard et al., , 1996 . However, there is a lack of direct evidence for the protein-protein interaction between LAG-3 and MHC-II. MHC-II was proposed to interact with LAG-3 through the residues on the membrane-distal, top face of the LAG-3 D1 domain (Huard et al., 1997) . Functionally, the MHC-II-CD4 interaction supported helper T cell activation, while overexpression of LAG-3 downregulated antigen-dependent CD4 + T cell responses in vitro (Workman and Vignali, 2003) . However, several mAbs that do not block the binding of LAG-3 to MHC-II nonetheless promoted T cell functions. For example, C9B7W, a specific mAb against the murine LAG-3 D2 domain, enhanced the proliferation and effector functions of T cells in vitro and in vivo (Workman et al., 2002b Workman and Vignali, 2005) . This antibody also increased the accumulation and effector function of tumor-specific CD8 + T cells in Table S1 ) in 1,536-well plates. LAG-3-Ig as well as fluorescence labeled anti-Fc mAb were added into each well for rapid detection of LAG-3-Ig binding. Human Fc receptors served as internal positive controls within each plate. Positive hits were confirmed by flow cytometry or Octet bio-layer interferometry. TM, transmembrane domain. several tumor models (Grosso et al., 2007; Woo et al., 2012) . The effects of C9B7W mAb on T cells are largely similar, if not identical, to those produced by LAG-3 genetic deficiency (Woo et al., 2012; Workman and Vignali, 2005) . A recent study also showed that anti-LAG-3 mAb that do not block MHC-II binding could still stimulate T cell activation and anti-tumor activity (Cemerski et al., 2015) . Given that LAG-3 also suppresses the function of CD8 + T cells and natural killer (NK) cells, which do not interact with MHC-II (Anderson et al., 2016) , these studies raise the possibility that the immunological functions of LAG-3 might be mediated via an unknown ligand.
Here, we report that fibrinogen-like protein 1 (FGL1) is a major functional ligand of LAG-3. FGL1 belongs to the fibrinogen family with high amino acid homology to the carboxyl terminus of the fibrinogen beta-and gamma-subunits, but it does not have the characteristic platelet-binding site, cross-linking region, and thrombin-sensitive site necessary for fibrin clot formation (Yamamoto et al., 1993) . Under normal physiological conditions, FGL1 protein is primarily secreted from hepatocytes and contributes to its mitogenic and metabolic functions (Demchev et al., 2013; Hara et al., 2001; Li et al., 2010; Liu and Ukomadu, 2008; Yamamoto et al., 1993; Yan et al., 2002) . The immunological function of FGL1, however, remains unknown. Our results demonstrate that FGL1 is a major inhibitory ligand for LAG-3, revealing a new mechanism of immune evasion.
RESULTS

FGL1 Is an MHC Class II-Independent High-Affinity Ligand of LAG-3
We employed our genome-scale receptor array (GSRA) technology to search for LAG-3 binding protein(s) using an immunoglobulin (Ig) Fc-tagged LAG-3extracellular domain fusion protein (LAG-3-Ig) ( Figure 1A) . The GSRA is a semi-automatic gene expression and detection system for rapidly identifying proteinprotein interactions, which has been modified from our previous report (Yao et al., 2011) . In this updated system, individual human cDNA encoding transmembrane and secreted proteins (upon addition of a transmembrane domain) were overexpressed on the surface of 293T cells. Several adaptor genes were also expressed in 293T (293T.2A cells) to facilitate protein expression on the cell surface ( Figure 1A ). An Ig-tagged protein of interest can then be screened for interaction(s) using the GSRA system in a high throughput fashion by the mix-andread laser scanning macro-confocal fluorescent plate reader. The current version of the GSRA contains over 90% of annotated genes encoding human transmembrane ($5,600) and secreted ($1,000) proteins (Table S1 ). FGL1 was identified as a major binding protein for LAG-3-Ig in the GSRA system ( Figures 1B  and S1A ). The FGL1-LAG-3 interaction is conserved across species in both human and mouse ( Figure 1B ). This interaction was further validated by flow cytometry, as indicated by a linear association between FGL1-Ig and anti-LAG-3 staining on LAG-3 + cells ( Figure 1C ). The FGL1-LAG-3 interaction was shown to have a K d value of $1.5 nM by Octet bio-layer interferometry analysis ( Figure 1D ). Using an SEC650 size exclusion column, the purified recombinant FLAG-tagged FGL1 (FLAG-FGL1) showed an oligomeric state (peak 1-2) and a dimeric peak (peak 3) ( Figure S1B ), which was validated via size exclusion chromatography with multi-angle light scattering analysis (SEC-MALS, data not shown). We observed stronger binding of the oligomeric forms of FLAG-FGL1 (peak 1-2) than the dimeric form (peak 3) to immobilized LAG-3-Ig in the Octet analysis ( Figure S1C ). In addition, the slow disassociation rate hints at a stable interaction between FGL1 and LAG-3 in both human and mouse ( Figures 1D and S1D ). FGL2, a homolog of FGL1 previously implicated in Treg functions (Shevach, 2009) , as well as other fibrinogen domain-containing family members such as angiopoietin-related proteins, did not bind LAG-3 ( Figure 1B and data not shown), indicating that the FGL1-LAG-3interaction is highly specific.
FGL1 is composed of a coil-coil domain (CCD) and a fibrinogen-like domain (FD) (Yamamoto et al., 1993) . Through domain deletion studies, we demonstrated that the FD, but not CCD, is responsible for LAG-3 binding ( Figure S1E ). The LAG-3 protein consists of four Ig-like extracellular domains, D1-D4 (Huard et al., 1997; Triebel et al., 1990) (Figure 1E , left). The deletion of the D3-D4 domain in LAG-3 did not affect FGL1 binding, while either D1 or D2 alone partially decreased the binding ( Figure 1E , right), suggesting that both D1 and D2 contribute to the FGL1-LAG-3 interaction. A single point mutation (Y73F) in the C 0 strand of LAG-3 D1 domain was previously shown to disrupt MHC-II binding (Huard et al., 1997; Workman et al., 2002a) . However, this mutation did not affect FGL1-Ig binding ( Figure 1E , right), indicating that the FGL1-LAG-3 interaction is non-redundant with MHC-II-LAG-3 binding. Furthermore, pre-incubation of (B) Image of the FGL1-LAG-3 interaction in GSRA system. 293T.2A cells were transfected with human (h) or mouse (m) FGL1-TM or full-length LAG-3 as indicated on the y axis. Human FGL2-TM was included as a negative control. The indicated fusion proteins shown on the x axis were added to the culture to evaluate binding to the transfectants by the cellular detection system (CDS). (C) Representative flow cytometry dot plot of FGL1-Ig binding to mouse LAG-3 + 293T.2A (blue) or mock cells (red). Control Ig binding to mouse LAG-3 + 293T.2A is also shown (brown). (D) Representative Octet sensorgrams showing various amounts of FLAG-tagged mouse FGL1 (starting from 10 mg/mL, 2-fold serial dilutions) binding to immobilized mouse LAG-3-Ig. (E) Schematic representation of constructs coding full-length mouse LAG-3, LAG-3 Y73F mutant, or LAG-3 with different extracellular domain deletions (left). LAG-3 full-length protein consists of four extracellular Ig domains (D1-D4), the transmembrane domain (TM), and intracellular domain (IC) (left). Quantification of FGL1-Ig binding to 293T.2A cells transfected to express LAG-3 with domain deletion/mutation (right). Data were analyzed by CDS software and presented as the mean ± SEM. ***p < 0.001, ****p < 0.0001, NS, not significant by Student's t test. (F) FGL1-Ig binding to mouse LAG-3 + 293T.2A cells in the presence of control mAb (black line) or anti-LAG-3 (red line) by flow cytometry. Cells stained with control Ig (shadow) served as a negative control. All data are representative of at least two independent experiments. See also Figure S1 . LAG-3 + 293T cells with C9B7W, an anti-LAG-3 mAb that binds the LAG-3 D2 domain without blocking the FGL1-MHC-II interaction (Andrews et al., 2017; Cemerski et al., 2015; Workman et al., 2002b) , led to complete abrogation of FGL1-LAG-3 binding ( Figure 1F ). Finally, LAG-3 + cells stained with MHC-II (I-A b ) fusion protein did not show a significant decrease in binding even in the presence of a 100-fold excess of FGL1-Ig (Figure S1F) . Taken together, our results indicate that FGL1 interacts with LAG-3 in an MHC-II-independent manner, and this interaction involves the FGL1 fibrinogen-like domain and the LAG-3 D1-D2 domain.
FGL1 Inhibits Antigen-Mediated T Cell Responses via LAG-3 In Vitro and In Vivo LAG-3 is not found on resting T cells other than a subset of Tregs but can be upregulated under various antigen stimulation conditions (Baixeras et al., 1992; Triebel et al., 1990; Workman et al., 2002b) . FGL1-Ig fusion protein did not bind resting T cells that express minimal LAG-3 levels (data not shown), although it did bind activated T cells from wild-type (WT) but not from LAG-3-KO mice, as determined via flow cytometry analysis (Figure 2A ). Inclusion of FGL1-Ig partially suppressed WT splenic T cell proliferation under suboptimal anti-CD3 stimulation, but this suppression was diminished using LAG-3-KO splenocytes (Figure 2B) , indicating that the suppressive effect of FGL1-Ig is dependent on LAG-3. Similarly, FGL1 better suppressed the antigen-specific induction of IL-2 from a murine LAG-3 overexpressing 3A9 T cell line (3A9-LAG-3) in a dose-dependent fashion compared to the parental 3A9 cell line with low endogenous LAG-3 expression ( Figure 2C ). We generated a mAb specific for mouse FGL1 (clone 177R4) that blocks FGL1-Ig binding to LAG-3 + 293T cells in a similar manner to anti-LAG-3 mAb C9B7W ( Figures S2A and S2B ). Both mAbs abrogated the suppression of FGL1 on IL-2 production from 3A9-LAG-3 cells ( Figure 2D ). Upon CD8 + OT-1 transgenic T cell transfer into syngeneic mice and subsequent immunization with chicken ovalbumin peptide antigen, administration of anti-FGL1 mAb 177R4 significantly promoted antigen-specific OT-1 T cell activation in a manner similar to anti-LAG-3 mAb, as determined by increased plasma levels of tumor necrosis factor alpha (TNF-a) and interferon (IFN)-g ( Figures S2C and S2D ). Thus, our results support that FGL1 is an inhibitory ligand of LAG-3.
Fgl1-Deficient Mice Slowly Develop Spontaneous Autoimmune Symptoms
We generated a Fgl1 gene knockout mouse strain (FGL1-KO) on the C57BL/6 background using an agouti color gene modified mouse ESC line (JM8) (Pettitt et al., 2009) . In WT mice, Fgl1 mRNA was detected in the liver but not in other organs or hematopoietic cells ( Figure S3A ). Soluble FGL1 was also detected in mouse blood ( Figure S3B ) as previously reported (Liu and Ukomadu, 2008) . In contrast, FGL1 was not detected in the plasma or liver of FGL1-KO mice via specific sandwich ELISA and western blot analysis, respectively ( Figures S3B and S3C ). FGL1-KO mice have an overall normal appearance, organ size, and litters, indicating that FGL1 does not globally affect the development and growth of mice. However, up to 40% (8/20) of FGL1-KO mice developed spontaneous dermatitis at the age of 8 months or older, showing lymphocyte infiltration in the dermis ( Figures S3D and S3E) . At 14-16 months of age, 5/8 female, but not male mice, had elevated levels of anti-double-stranded DNA autoantibodies in their plasma compared to WT mice ( Figure S3F ). These findings are consistent with the role of FGL1 as an immune suppressive molecule. To evaluate overall changes in the immune system of this KO strain, we profiled mouse peripheral blood cells by mass cytometry (CyTOF), a single cell high dimensional analysis tool using 32 metal-conjugated mAbs to determine immune cell lineages as well as functional molecules. A recently described unsupervised clustering method named x-shift was also employed (Samusik et al., 2016) . Analysis of the total CD45 + hematopoietic cells revealed 22 distinct cell type or subsets (clusters), with small but significant increases in central memory-like CD8 + T cells subsets (cluster 14-15, CD44 + CD62L + Ly6C + CD127 med Tbet + Eomes + ) and decreases in two B cell subsets (cluster 2 and 4) ( Figures  3A-3E ). All other clusters were similar in FGL1-KO compared to WT mice ( Figures 3A-3E ). There were no major differences in T cells or myeloid cell subsets in peripheral lymphoid tissues including the spleen or liver (data not shown).
These findings indicate that endogenous FGL1 does not affect mouse development and growth, although it may participate in regulating autoimmunity and immune homeostasis in aged mice.
Fgl1 Silencing Promotes T Cell Immunity against Tumor Growth in Mouse Models FGL1-KO and LAG-3-KO mice were inoculated subcutaneously (s.c.) with syngeneic murine MC38 colon cancer cells. Similar to LAG-3-KO mice, FGL1-KO mice showed significantly slower tumor growth in comparison to WT mice ( Figure 4A ). Whereas all of the WT mice reached an endpoint (average mean tumor diameter of 15 mm) within 60 days, $50% of FGL1-KO or LAG-3-KO mice were tumor-free beyond 200 days upon MC38 inoculation ( Figure 4B ). Similarly, both anti-FGL1 and anti-LAG-3 mAbs significantly controlled tumor growth of established MC38 murine colon ( Figure 4C ) and Hepa1-6 murine liver cell lines inoculated s.c. in syngeneic C57BL/6 mice ( Figure S4A ). In contrast, the anti-FGL1 and anti-LAG-3 mAb antitumor effect was abrogated in Rag1-KO C57BL/6 mice, which are devoid of T and B cells ( Figure 4D ). Consistent with these findings, depletion of either CD8 + or CD4 + T cells by specific mAbs completely eliminated the anti-tumor effect of both anti-FGL1 and anti-LAG-3 mAb in the MC38 tumor model, indicating that the anti-tumor effect of these mAbs is dependent on both CD8 + and CD4 + T cells ( Figure S4B ).
To exclude the possibility that additional ligands for LAG-3 are functionally redundant to FGL1 and contribute to the anti-tumor effect of the anti-LAG-3 mAb, we tested the effect of anti-LAG-3 mAb in FGL1-KO mice. While the anti-LAG-3 mAb suppressed MC38 tumor growth in WT mice, this anti-tumor effect was completely eliminated in FGL1-KO mice ( Figure 4E ). The effect of anti-FGL1 was also dependent on LAG-3, as this mAb did not have additive effects on tumor growth in LAG-3-KO mice ( Figure 4F ). Therefore, the anti-tumor effect of anti-FGL1 mAb is dependent on LAG-3, whereas the effect of anti-LAG-3 relies on FGL1 but not MHC-II or other LAG-3 ligands. Altogether, our findings support FGL1 as a major ligand for LAG-3 to induce T cell suppressive function and immune evasion.
The deficiency of FGL1 significantly reduced MC38 tumor growth while spleen size and the number of lymphocytes in either tumor-draining or non-tumor-draining lymph nodes remained similar ( Figure S4C ). Analysis of tumor-infiltrating leukocytes (TIL) in tumors excised on day 17 from FGL1-KO and WT mice by mass cytometry revealed a significant increase of CD45 + leukocytes in FGL1-KO tumors ( Figure S4D ). In 22 clusters across CD45 + cells ( Figures 5A and 5B ), we found a significant expansion of CD44 + CD62L À PD-1 + Gata3 + effector memory-like CD4+ TIL (cluster 2 and 3), as well as CD44 + Ly6C + memory-like CD8 + (De-Long et al., 2018; Pihlgren et al., 1996; Walunas et al., 1995) TIL populations (clusters 8-10) in FGL1-KO tumors ( Figures 5B-5E ). In contrast, Treg (cluster 1), NK (cluster 11), or B cells (cluster 14) did not change significantly ( Figures 5B-5E ). Interestingly, a natural killer T (NKT) population (cluster 12) was highly expanded in the FGL1-KO tumors, in comparison with a significant decrease of F4/80 + CD11b + MHC-II + CD11c med tumor-associated macrophages (cluster 15) ( Figures 5C-5E ). Confirming this data, we also observed a significant increase in the absolute number of leukocytes (CD45 + cells), CD8 + , and CD4 + TIL per mg of tumor tissues in mice treated with anti-FGL1 or anti-LAG-3 mAbs compared to control treated mice ( Figure S4E ). Furthermore, there was a significant increase in activation or functional markers, such as CD69, Ly6C, granzyme B (GZB), CD4, and FAS, in CD4 + or CD8 + TIL from anti-FGL1 or anti-LAG-3 treated mice ( Figure S4F ). Our results indicate that silencing the FGL1-LAG-3 interaction by either genetic knockout or antibody blockade promotes tumor immunity by stimulating T cell expansion and activation preferentially in the tumor microenvironment.
FGL1 Is Upregulated in Human Cancers
FGL1 mRNA and protein expression is largely limited to the liver and pancreas of human normal tissues according to the BioGPS tissue microarray database and proteome analysis (Kim et al., 2014 ) ( Figure S5A ). Meta-analysis of the Oncomine databases revealed the upregulation of FGL1 mRNA in human solid tumors including lung cancer, prostate cancer, melanoma, and (C and D) B6 (C) or Rag1-KO (D) mice were inoculated with MC38 cells (0.5 3 10 6 /mouse) at day 0 and treated with anti-FGL1, anti-LAG-3, or control mAbs every 4 days from day 6 to day 18. The mean tumor diameters in each group (n = 6) are shown. (E) WT or FGL1-KO mice were inoculated with MC38 cells and were treated with anti-LAG-3 or control mAb as in (C). The mean tumor diameters in each group (n = 6-8) are shown. (F) LAG-3-KO mice were inoculated with MC38 cells and were treated with anti-FGL1 (n = 8) or control mAb (n = 7) as in (C). The mean tumor diameters in each group are shown. Data were representative of at least two independent experiments and are shown as the mean ± SEM. *p < 0.05; **p < 0.01; NS, not significant. (A) and (C-F) by two-way ANOVA; (B) by log-rank test. See also Figure S4 . (legend continued on next page) colorectal cancer compared to normal tissues, with the highest percentage of upregulation (8/23, or 35%) in lung cancer datasets, while its expression appeared to be downregulated in pancreas, liver, and head and neck cancers ( Figure S5B ). Furthermore, FGL1 is one of the most upregulated genes in The Cancer Genome Atlas (TCGA) database for lung adenocarcinoma ( Figure S5C ; Table S2 ). FGL1 is also significantly upregulated in prostate or breast cancer but is downregulated in liver cancer within this database ( Figure S5C ). We established a multiplex quantitative immunofluorescence (QIF) assay to detect FGL1 protein expression on cells and tissues. In addition, a quantitative sandwich ELISA was also established to detect secreted FGL1 in human plasma (see STAR Methods). A 293T line constitutively expressing FGL1 and human tissue samples were utilized to standardize the assay in FFPE preparations and establish the signal detection threshold ( Figure S6A ). As expected, levels of FGL1 protein were highest in a cell line transfected to express the FGL1 gene ( Figure S6A ) and human liver (data not shown), but low or undetectable in mock-transfected cells ( Figure S6A ) or samples from human testis and skeletal muscle (data not shown). We then evaluated the localized expression of FGL1 in 275 non-small cell lung carcinomas (NSCLC) presented in tissue microarray format (cohort #1, from Yale University, also see Table S3 ) by simultaneous staining of FGL1 and pan-cytokeratin using multiplex QIF staining. In NSCLC, FGL1 protein was found localized in tumor cells (the pan-cytokeratin-positive) with minimal expression in the stromal compartment (the pan-cytokeratin-negative) ( Figure 6A ) and no expression in paired normal lung tissues ( Figure S6B ). Tissue FGL1 levels showed a continuous distribution in this cohort and $15% of specimens from NSCLC patients showed elevated expression ( Figure 6B ) which was associated with a significantly decreased 5-year overall survival ( Figure 6C ). Interestingly, there was no association between FGL1 and B7-H1 (PD-L1) expression levels, but high FGL1 in tumor tissue was significantly associated with high LAG-3 levels ( Figure S6C ). In addition, we also found significantly higher plasma FGL1 levels in NSCLC patients compared to healthy donors in two independent cohorts (see also Table S3 ): cohort #2 (n = 18) from University of Navarra, Pamplona, Spain ( Figure 6D ) and cohort #3 (n = 56) from Fujian Medical University, Fuzhou, China (Figure S6D ). Of note, there was no difference in plasma FGL1 levels among NSCLC patients with or without metastasis as well as liver injury ( Figure S6E ). Furthermore, in cohort #2, we found a positive association of tumor FGL1 QIF scores and plasma FGL1 levels (data not shown). Our findings indicate that FGL1 is upregulated in human cancers, especially in NSCLC.
High Plasma FGL1 Is Associated with Poor Outcomes in Patients with Anti-PD Therapy
To test if FGL1 acts independently from the B7-H1-PD-1 pathway to suppress tumor immunity, we evaluated the associ-ation between the baseline plasma FGL1 levels and the efficacy of the B7-H1-PD-1 blockade therapy (anti-PD therapy) in metastatic NSCLC patients. In cohort #2 (see also Tables S3 and S4) , we found that higher plasma FGL1 levels were associated with worse overall survival in NSCLC patients treated with anti-PD therapy (hazard ratio [HR] = 6.8, 95% confidence interval [CI] = 1.1-42 and p value = 0.04) ( Figure 6E) . Similar results were observed in an independent cohort (cohort #4, from Yale University, see also Tables S3 and S4 ) of metastatic melanoma patients (n = 21) treated with anti-PD-1 mAbs (HR = 7.9; 95% CI = 2.2-27.4 and p value <0.001) ( Figure 6F ). Our results suggest that the FGL1-LAG-3 interaction is independent from the B7-H1-PD-1 pathway and could potentially contribute to the resistance of anti-PD therapy in human cancers.
We further tested the role of the anti-FGL1 or anti-LAG-3 in the presence of the B7-H1-PD-1 pathway blockade using the MC38 tumor model. Mice were inoculated s.c. with MC38, and established tumors at day 6 were treated with the mAbs. When applied individually, anti-FGL1, anti-LAG-3, or anti-B7-H1 mAb slowed tumor growth and minimally prolonged survival ( Figure 6G ). However, anti-FGL1 or anti-LAG-3 mAb in combination with anti-B7-H1 mAb significantly improved survival ( Figure 6G ) and decreased tumor burden ( Figure 6H ) compared to single mAb treatment. A significant proportion of mice (>30% of mice) treated with the combination therapy were free of tumor for over 150 days ( Figure 6G ). Our results suggest that the FGL1-LAG-3 pathway is an independent tumor immune evasion mechanism, and blockade of this interaction may synergize with anti-PD therapy.
DISCUSSION
In this study, we have identified and characterized FGL1 as a major ligand of LAG-3 that is responsible for its T cell inhibitory function in a receptor-ligand interdependent manner both in vitro and in vivo. Genetic ablation or mAbs blocking the FGL1-LAG-3 interaction enhanced T cell responses and promoted anti-tumor immunity. With limited expression in the majority of normal tissues, FGL1 is upregulated in several human cancers and is associated with a poor prognosis and therapeutic outcome. Together, our findings support the FGL1-LAG-3 pathway as an immune escape mechanism and a potential target for cancer immunotherapy.
Physiological functions of FGL1 are not well understood. Soluble FGL1 protein can be detected in the blood plasma of healthy donors at the ng/mL level, while FGL1 mRNA can only be detected in liver and pancreas across a large panel of normal tissues ( Figure S5A ), suggesting that FGL1 may be produced by the liver and/or pancreas and subsequently released into the bloodstream. In addition to the reported function in hepatocyte regeneration and metabolism, our findings reveal for the first time a prominent role of FGL1 in the negative regulation of inflammatory immune responses. FGL1-KO mice spontaneously developed several autoimmune symptoms including dermatitis and anti-dsDNA autoantibodies ( Figures S3D-S3F ). However, these symptoms developed only in the aged but not in newborn or young adult mice, indicating that endogenous FGL1 is not a major regulator for self-tolerance but may suppress environmentally induced inflammation. Interestingly, liver is considered an immune-privileged organ, as allogeneic liver transplants can survive longer without immune suppressive agents (Horst et al., 2016) . The underlying mechanism for this immune privilege, however, is largely unknown. We did not observe significant liver inflammation in aged FGL1-KO mice (data not shown), perhaps due to a lack of LAG-3 expression on resting T cells in the liver. While FGL1 may play a local role in maintaining the tolerogenic environment of the liver, its secretion as a soluble factor allows for potential cross-talk between the liver and other peripheral tissues that may help fine-tune systemic inflammation. This normal physiological function of FGL1 may be hijacked by several solid tumors that increase FGL1 expression to suppress local anti-tumor immunity. In this context, immune evasion may be mediated by high levels of FGL1 in the tumor microenvironment through the interaction with LAG-3 specifically expressed on tumor-infiltrating T cells.
Our results in mouse tumor models indicate a preferential activation of T cell immunity in the tumor microenvironment upon FGL1-LAG-3 blockade while the effect of this blockade in systemic immune suppression is minimal (unpublished data), suggesting a major role for FGL1 in immune suppression of the tumor microenvironment.
Our results support FGL1 as a major ligand for the T cell inhibitory function of LAG-3. First, FGL1-LAG-3 represents a high-affinity interaction that is specific and physiological, as indicated by fusion protein binding experiments involving primary T cells from WT or Lag3-deficient mice. Second, FGL1 mAb has similar effects to anti-LAG-3 on the stimulation of T cell responses and antitumor effect in our in vitro and in vivo experiments. Furthermore, anti-FGL1 mAb has no antitumor effect in LAG-3-deficient mice while anti-LAG-3 mAb likewise loses efficacy in Fgl1-deficient mice. Finally, our preliminary studies indicate that adult Fgl1-deficient mice are also prone to the induction of autoimmune diseases (unpublished data), a phenotype similar to LAG-3-deficient mice (Bettini et al., 2011; Woo et al., 2012) .
To date, at least four different proteins have been reported to interact with LAG-3 including MHC-II, galectin-3, LSECtin, and a-synuclein. Galectin-3 and LSECtin have potential roles in T cell regulation, while a-synuclein is possibly involved in the neurological function of LAG-3 (Kouo et al., 2015; Mao et al., 2016; Xu et al., 2014) . The interaction modality of galectin-3 and LSECtin to LAG-3 are less known, but both molecules have previously been shown to have several other binding partners (Kizuka et al., 2015; Li et al., 2009; Liu et al., 2004; Stillman et al., 2006; Tang et al., 2010) . It remains to be shown whether their roles in the suppression of T cell-responses and antitumor immunity are dependent on LAG-3. Although MHC-II is the first identified ligand for LAG-3, the detailed biochemistry and affinity of this interaction is still unclear. Given that FGL1 does not compete with MHC-II for LAG-3 binding ( Figure S1F ), this opens the possibility for the existence of a FGL1-MHC-II-LAG-3 trimolecular complex-open questions include the signaling outcome of FGL1 versus MHC-II upon interaction with LAG-3 and how this complex could contribute to T cell suppression. A detailed stoichiometry analysis may be required to understand how soluble FGL1 triggers cell surface LAG-3 to transmit signals for T cell suppression, which is currently unknown. We found that FGL1 could form oligomers, and these oligomeric forms of FGL1 bound to LAG-3 much better than the dimeric form ( Figures S1B and S1C) , implicating that oligomeric FGL1 may be required for T cell suppression. The presence of native oligomeric FGL1 may also explain our results in the Octet assay showing a high-affinity interaction of purified soluble FGL1 with LAG-3. Thus, increased avidity of FGL1, most likely through oligomerization, but potentially through other mechanisms such as attachments to the extracellular matrix, may facilitate its interaction with LAG-3 in vivo. Currently, several MHC-II blocking anti-LAG-3 mAbs are being evaluated in clinical trials for the treatment of advanced human cancer. Preliminary data of these trials showed minimal or modest effect as a single agent (Ascierto and McArthur, 2017; . Based on our findings, a possible interpretation for the clinical results could be that these mAbs block the MHC-II-LAG-3 interaction but do not block FGL1-LAG-3 binding. Thus, these mAbs may still allow FGL1 to transmit inhibitory signals to LAG-3, leading to an incomplete blockade of LAG-3-mediated immune suppression. Our findings warrant careful re-evaluation of (B and C) FGL1 expression as indicated by quantitative immunofluorescence (QIF) staining in NSCLC cancer tissues from cohort #1 (see also Table S3 ). (B) Distribution of FGL1 expression and (C) association of high or low FGL1 expression with overall survival of the patients. The QIF visual detection threshold (1010.27) was used as a cutoff as indicated by dotted line in (B). (D) The baseline plasma FGL1 levels were determined by ELISA in cohort #2 (see also Table S3 ) of NSCLC cancer patients (n = 18) and healthy donors (n = 16). Data were presented as the mean ± SEM. ***p < 0.001 by Student's t test.
(E and F) Kaplan-Meier plots of overall survival stratified by median baseline plasma FGL1 levels in NSCLC (cut-point: 336.5 ng/mL) and melanoma (cut-point: 114 ng/mL) patients treated with single-agent anti-PD-1 therapy in NSCLC (D, cohort #2, n = 18) and melanoma (E, cohort #4, n = 21). See also Tables S3 and S4. (G and H) B6 mice were inoculated s.c. with MC38 cells (0.5 3 10 6 /mouse) at day 0, followed by the treatment with anti-FGL1, anti-LAG-3, or control mAb (n = 6 per group) every 4 days from day 6 to day 18. In some groups, mice were also treated with a single dose of anti-B7-H1 (10B5) at day 6. (G) Survival of the mice is shown. Survival analysis was conducted by log-rank test, **p < 0.01; ***p < 0.001. The presented data is representative of at least two independent experiments. (H) Tumor sizes are shown as the mean tumor diameter ± SEM at day 22. **p < 0.01 by Student's t test. See also Figures S5 and S6 and Table S2 . therapeutic strategies that aim to block the immune inhibitory function of LAG-3.
Our findings support that the FGL1-LAG-3 pathway maybe an important immune evasion mechanism and could contribute to current cancer immunotherapy efforts for several reasons. Our studies indicate that FGL1 is a major ligand for LAG-3 to suppress T cell responses and constitute a new target for immune modulation. Furthermore, upregulation of FGL1 on tumor cells but not in normal tissues ( Figure S5 ) may allow for a highly tumor-selective targeting of antibody therapy. In addition, tumor model studies using FGL1-KO mice demonstrate that FGL1 has a potent immune suppressive effect on anti-tumor immunity that is dependent on LAG-3. FGL1-LAG-3 interaction may also affect the generation of memory T cells as shown by our CyTOF data of increased memory-like CD4+ and CD8+ T cells in TILs from FGL1 KO mice during tumor growth ( Figure 5 ) and an association of low FGL1 level with long-term survival of cancer patients upon anti-PD therapy ( Figure 6E and 6F) . Moreover, FGL1 may be a potential biomarker to predict the outcome of anti-PD therapy, since high plasma FGL1 levels are associated with a worse response to anti-PD therapy in NSCLC and melanoma patients (Figures 6E and 6F) . Lastly, FGL1 blockade also synergizes with anti-B7-H1 blockade in animal models ( Figures 6G and 6H ), suggesting that FGL1 and anti-PD dualblockade may be an alternative treatment for patients who are resistant to anti-PD therapy. In summary, our findings identify a functional interaction of the LAG-3 pathway and reveal a possible mechanism that tumors may employ for immune evasion, with important implications for developing next generation cancer immunotherapies.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Female C57BL/6 (B6) mice, Rag1À/À (herein referred to as Rag1-KO) and OT-1 Rag1-KO mice at 6-8 weeks old were purchased from Charles River (Wilmington, MA) and Taconic Biosciences (Rensselaer, NY), respectively. Fgl1 gene conditional knockout mice were obtained from European Mouse Mutant Archive (EMMA), and homologous targeting of this mouse strain was performed in a genetically engineered B6 ES cell (Agouti JM8A). Fgl1 whole body knockout mice (Fgl1À/À, herein referred to as FGL1-KO) were generated by crossing Fgl1 gene conditional knockout mice with CMV-Cre mice (Jackson Laboratory). The Lag3 whole body knockout mice (Lag3À/À, herein referred to as LAG-3-KO) were described previously (Workman and Vignali, 2003) . All mouse protocols were in accordance with NIH guidelines and approved by the Animal Care and Use Committee of Yale University School of Medicine.
Plasmids, fusion proteins and antibodies
The human cDNA library constructs coding $5600 full-length plasma membrane proteins and $1000 secreted proteins were purchased from Genecopoeia (Rockville, MD), Open Biosystems (Huntsville, AL) or were individually cloned by Chen laboratory at Yale. All of the genes used for the GSRA were cloned into a mammalian expression vector. Human and mouse fusion proteins were generated by tagging the extracellular domain with human Ig Fc or 3xFLAG, expressed in 293T cells, and purified by affinity column, or purchased from R&D systems (Minneapolis, MN) . The domain deletion plasmids for FGL1 and LAG-3 were produced by PCR or GeneArt synthesis (Thermo Fisher, Waltham, MA). Antibodies used in flow cytometry and in vitro studies were purchased from BD Biosciences (San Jose, CA), BioLegend (San Diego, CA), or Thermo Fisher (Waltham, MA). Mouse CD8 or CD4 in vivo depletion antibodies were purchased from BioXcell (West Lebanon, NH). The hybridoma (clone C9B7W) producing anti-murine LAG-3 mAb was described previously (Workman et al., 2002b) . The methods to produce and characterize the panels of rat anti-mouse FGL1 and mouse anti-human FGL1 were described previously by immunization with relevant fusion protein (Chen et al., 1992; Dong et al., 2002) . The 177m03/177R4 antibodies were also used for flow cytometry and immunohistochemistry. The 177R8 antibody was used for the detection of FGL1 in the mouse liver by western blot.
Human subjects
All four patient cohorts are summarized in Table S3 . Cohort #1 (Yale University) included tumor samples in the form of tissue microarrays (TMAs) from 275 NSCLC patients who were not treated with immunotherapy. Cohort #2 (University of Navarra) included plasma samples collected from 18 NSCLC patients who were treated with anti-PD-1 mAbs. Cohort #3 (Fujian Medical University) included plasma samples from 56 NSCLC patients who were not treated with immunotherapy. Cohort #4 (Yale University) included plasma samples from 21 melanoma patients treated with anti-PD-1 mAbs. The treatment characteristics of patients in cohort#2 and #4 are summarized in Table S4 and the plasma samples were collected before anti-PD-1 treatment. The study protocols were approved by the Institutional Review Boards from each participating institution and all patients signed written informed consents. Human peripheral bloods were obtained by venipuncture and centrifuged to isolate plasma that were stored at À80 C.
METHOD DETAILS
The genome-scale receptor array system The genome-scale receptor array (GSRA) system was modified from our previous report (Yao et al., 2011) . Other than $5,600 genes encoding cell transmembrane proteins, over 1,000 genes encoding secreted proteins were also included in the GSRA system. The gene selection criteria include the expression profiles and homology with known immune-related gene families (bioinformatics analysis using BioGPS, Immgen, HPM, UCSC genome browser and NCBI databases). The selected genes coding secreted proteins were fused with an artificial transmembrane domain (TM) from FIBCD1 (TM insertion into the N-terminal) or B7-H6 (TM insertion into the C-terminal) to ensure membrane expression. In each plate, cDNA library plasmids were diluted individually in OptiMEM (4ug/ml) before transferring into 384-well plates (VWR) with 200ul plasmid solution in each well. Two uls of plasmid solution from each well were further transferred into 1536-well plates (Greiner) by a robotic liquid handling system (PlateMate, ThermoFisher) and stored at À80 C. For the assay, 2 ul OptiMEM containing Lipofectamine 3000 per well was added to the plates with a Multidrop Combi robotic dispenser (Thermo Fisher), followed by the addition of 2,000 293T.2A cells (a 293T subline overexpressing DAP10, DAP12, FcRg and CD3Z) in 4 ul DMEM medium per well. After incubation at 37 C for 18 hr, 2 ng of LAG-3-Ig (human or mouse) and 3 ng of anti-Fc secondary antibody were added into each well. These plates were read 8 hr later in the Applied Biosystems 8200 cellular detection system (CDS) and analyzed by the CDS 8200 software. Human Fc Receptors were served as internal positive controls within each plate.
Protein-protein interaction analysis
Recombinant proteins were purified by HiTrap Protein A column (GE Healthcare) or anti-FLAG M2 affinity gel (Sigma). In some experiments, different protein fractions of size exclusion chromatography (SEC) by SEC650 column (BioRad) were collected, and then performed for a size exclusion chromatography with Multi-Angle Light Scattering analysis (SEC-MALS) for absolute molecular mass and size measurements using Agilent 1200 system (Agilent Technologies) equipped with Superdex 200 column (GE Healthcare). Protein interactions were measured and analyzed by an Octet Red instrument (PALL, NY). The Octet Protein A sensor was dipped into solution containing mouse or human LAG-3-Ig fusion protein (10ug/ml) and subsequently loaded with various concentrations of FLAG tagged FGL1 proteins (two-fold serial dilutions) or their different SEC peak fractions (10ug/ml). Protein association and disassociation was monitored and analyzed by Octet software, and the Kd value was calculated using 1:1 binding ratio.
T cell function assays T cell costimulation assay was described previously (Chapoval et al., 2001; Sica et al., 2003) . Briefly, anti-mouse CD3 mAb (eBiosciences) at suboptimal concentrations were pre-coated in 96-well flat plates. Splenocytes from wild-type B6 mice or LAG-3-KO mice at 3x10 5 /well were added in the presence of FGL1-Ig or control Ig at 5ug/ml and cultured at 37 C for 3 days. In the last 16 hr of culture, 3 H-TdR was added and counted with a MicroBeta Trilux liquid scintillation counter (PerkinElmer, Waltham, MA). For antigen-specific stimulation, 3A9 T cell hybridoma (with low endogenous LAG-3 expression) or 3A9 overexpressing mouse LAG-3 gene (3A9-LAG-3) was incubated with LK35.2 cell line as antigen-presenting cells in the presence of HEL peptide (1.5ug/ml) and recombinant FGL1 or control protein at the indicated concentrations. Anti-FGL1(177R4) or anti-LAG-3 antibodies (5ug/ml) were also included at the beginning of the culture. The serum free medium (CellGenix) was used for this assay and the IL-2 levels in the supernatant 24 hr after exposure to antigens were analyzed by CBA kit (BD PharMingen).
Syngeneic mouse tumor models
Female 8-10-week-old LAG-3-KO, FGL1-KO mice or wild-type littermates (WT) were inoculated s.c. with MC38 (5 3 10 5 /mouse) or Hepa1-6 (1x10 6 /mouse) at day 0 and subsequently treated intraperitoneally (i.p.) with 100 ug of anti-FGL1(177R4) or anti-LAG-3 (C9B7W) mAbs on days 6, 10, 14 and 18, with saline or rat-Ig as controls. Anti-B7-H1 (10B5) (Dong et al., 2002; Hirano et al., 2005) at 100ug was injected i.p. at day 6. Tumor growth was monitored by electronic caliper twice a week and shown as the mean tumor diameter: (length + width)/2 (Chen et al., 1992 (Chen et al., , 1994 .
Mouse tissue digestion
Mouse tumor tissues were mechanically dissociated with the GentleMACS Dissociator (Miltenyi Biotec) in the presence of RPMI 1640 with 1mg/ml Collagenase IV plus 0.1mg/ml DNase I (Sigma-Aldrich) for 30 min at 37 C. Cell suspension was washed with RPMI containing 10% FBS (GIBCO) and filtered through 70-mm cell strainer (BD Falcon).
Mass cytometry sample preparation
Cells from tumor tissue were re-suspended in PBS with 0.5% BSA and 0.02% NaN3 and incubated with mAb against mouse CD16/ 32 for 10 min at room temperature to block Fc receptors. Subsequently metal-labeled mAbs cocktail against cell surface molecules were added and further incubated for 20 minutes on ice. Antibodies were either purchased pre-conjugated from Fluidigm or conjugated in-house using mass cytometry antibody conjugation kits (Fluidigm) according to the manufacturer's instructions. Cells were stained for viability with 5mM cisplatin in FBS (Fluidigm) for 1 minutes on ice. After the treatment with the Fixation/Permeabilization Buffer (Thermo Fisher), cells were further incubated with the metal-labeled mAbs cocktail against intracellular proteins. Cells were then washed and stained with 1 mL of 1:4000 191/193Ir DNA intercalator (Fluidigm) diluted in PBS containing 1.6% Paraformaldehyde (EMS), and stored at 4 C until acquisition.
Mass cytometry sample acquisition
At the moment of acquisition, cells were washed once with PBS with 0.5% BSA and 0.02% NaN3, once with ddH2O, and then resuspended in ddH2O containing bead standards (Fluidigm) to approximately 10 6 cells per ml. Samples were subsequently acquired on a CyTOF2 machine (Fluidigm) at an event rate of < 400 events/second.
Quantitative multiplex immunofluorescence
Simultaneous and quantitative multiplex immunofluorescence (QIF) protocol was developed as previously described (Schalper et al., 2015) using specific antibodies for indicated antigens carefully titrated and validated individually. Briefly, fresh histology sections from the cases were deparaffinized and subjected to antigen retrieval using EDTA buffer (pH = 8.0) and boiled for 20 min at 97 C in a pressure-boiling container (PT module, Lab Vision). Slides were then incubated with dual endogenous peroxidase block (DAKO #S2003, Carpinteria, CA) for 10 min at room temperature and subsequently with a blocking solution containing 0.3% bovine serum albumin in 0.05% Tween solution for 30 minutes. Slides were stained with 4', 6-Diamidino-2-Phenylindole (DAPI) for visualization of all cell nuclei, and simultaneously stained with anti-FGL1 (clone 177m03) as well as antibody to pan-cytokeratin (CK, clone AE1/AE3, Abcam). In some experiments, the slides were co-stained with antibodies to LAG-3 (clone 17B4, Abcam) or B7-H1(clone 405-9A11, Cell signaling). Secondary antibodies and fluorescent reagents were later included for the detection of the signal of each marker, including anti-mouse Envision (K4001, DAKO) with Cy5-tyramide (Perkin-Elmer), anti-mouse IgG1 antibody (Abcam) with Cy3 plus (Perkin-Elmer), goat anti-rabbit (Abcam) with biotinylated tyramide/Streptavidine-Alexa750 conjugate (Perkin-Elmer).
Residual horseradish peroxidase activity between incubations with secondary antibodies was eliminated by exposing the slides twice for 10 minutes to a solution containing benzoic hydrazide and hydrogen peroxide.
Measurement of plasma FGL1 levels
Two pairs of anti-FGL1 antibodies were used to measure FGL1 levels in the plasma of human (177m01&177m03) or mouse (177R1&177R4) samples by the sandwiched enzyme-linked immunosorbent assay (ELISA). The assay diluent (PBS with 10%FBS) served as negative control.
QUANTIFICATION AND STATISTICAL ANALYSIS
Mass cytometry data analysis All mass cytometry files were normalized and manually gated in FlowJo (version X 10.0.7r2) or Cytobank (Santa Clara, CA) by DNA, event length, live/dead discrimination, CD45, and 4 bead channels to exclude dead, debris, doublets, and non-immune cells and beads. Data were arcsinh transformed with a cofactor of 5 before applying the downstream analyses. X-shift clustering analysis (Samusik et al., 2016) in Java was performed to pooled samples to automatically identify underlying immune subsets. Heat-maps were generated with selected markers, which had been normalized by dividing the 99% percentile of cluster mean value for each marker. Cell frequency in each cluster was calculated as the assigned cell events dividing the total cell events in the same sample after manual gating. Clusters with less than 1% cell frequency for all samples were not displayed in frequency plot or heat-maps in order to increase the clarity of visualization. t-Distributed Stochastic Neighbor Embedding (t-SNE) dimension reduction was performed using R package (van der Maaten and Hinton, 2008) to WT/FGL1-KO tumors and PBMC datasets. Each sample was randomly sampled for up to 5,000 cells to ensure the total displayed cell events in WT and FGL1-KO scenarios were equivalent. For analysis of antibody treatment data, FCS files were manually pre-gated on Ir193 DNA + CD45 + events, excluding cisplatin + dead cells, doublets and DNA-negative debris, and analyzed by Cytobank (Santa Clara, CA).
Tissue fluorescence measurement and scoring
Quantitative measurement of the fluorescent signal was performed using the AQUAâ method that enables objective and sensitive measurement of targets within user-defined tissue compartments. Briefly, the QIF score of each marker expression was calculated by dividing the corresponding antibody staining pixel intensities by the area of cytokeratin (CK) positive tumor compartment or the DAPI positive total tissue compartment. Scores were normalized to the exposure time and bit depth at which the images were captured, allowing scores collected at different exposure times to be comparable.
Bioinformatics and statistics
The FGL1 expression pattern in normal human or mouse tissues as well as leukocytes were analyzed in BioGPS and HPM databases. The mRNA microarray data on solid cancers and the counterpart normal tissues (254 datasets in total covering 14 types of human cancers) were collected from Oncomine (Thermo Fisher). FGL1 upregulation or downregulation frequency in the datasets of each cancer (fold change R 3 for upregulation, or < 0.3 for downregulation, and p value < 0.05 as cutoff) were further analyzed by the program R. Moreover, FGL1 expression in individual cancer versus counterpart normal tissues was also evaluated using TCGA cancer databases. The original microarray data was normalized by cancer browser (http://xena.ucsc.edu/welcome-to-ucsc-xena/) and then analyzed by the program R. Student's t test, two-way ANOVA, and Log-rank test on GraphPad Prism 7.0 was used for statistical analysis, and p values reflect comparison to the control samples. P values were reported as follows: NS, not significant, *, p < 0.05; **, p < 0.01; ***, p < 0.001, ****, p < 0.0001. The error bars in figures represent standard error of the mean (SEM).
DATA AND SOFTWARE AVAILABILITY
The CyTOF FCS files associated with the datasets in this paper have been uploaded in Mendeley database with the following preview link: https://data.mendeley.com/datasets/8gvfpy83jn/draft?a=e1bb6f8d-a1f8-481f-a465-142dabd0f24b. The purified FLAG-tagged mouse FGL1 showed three peaks in the SEC650 size exclusion column, the typical oligomeric state (peak1-2) and a dimeric peak 3 (validated by SEC-MALS, $77.6 kD). (C) Octet analysis of mouse FGL1-LAG-3 interaction. The Octet Protein A sensor was loaded with mouse LAG-3-Ig and then tested for binding kinetics with oligomeric (peak 1-2) or dimeric form (peak 3) of FLAG-tagged mouse FGL1 (10ug/ml) as well as the control PBS buffer. (D) Octet analysis of human FGL1-LAG-3 interaction. The Octet Protein A sensor was loaded with human LAG-3-Ig and then tested for binding kinetics with FLAGtagged human FGL1 (starting from 100ug/ml, two-fold serial dilutions). with Hepa1-6 cells at 1x10 6 /mouse (a), or MC38 cells at 0.5x10 6 /mouse (b) as described in Figure 4C , followed by the treatment with anti-FGL1, anti-LAG-3, or control mAb (n = 5 per group). Some groups of mice (b) were additionally treated with either anti-CD8 (middle panel) or anti-CD4 (right panel) depleting mAb twice a week from day 1 after tumor inoculation. Tumor growth is shown as mean tumor diameter ± SEM. *p < 0.05; NS, not significant by Two-way ANOVA.
Supplemental Figures
(C and D) FGL1-KO or WT mice were inoculated with MC38 cells at day 0 and euthanized at day 17 as in Figure 5 . The weight of tumor or spleen, as well as the total numbers of tumor-draining (TDLN) or non-tumor-draining (LN) lympho-node are shown (c). In addition, the percentage of CD45+ leukocytes in the tumor single cell population, and absolute number of CD45+ cells per mg tumor tissue is shown (d). *p < 0.05; NS, not significant by Student's t test.
(E and F) B6 mice were inoculated s.c. with MC38 cells at 0.5x10 6 /mouse, followed by the treatment with anti-FGL1, anti-LAG-3, or control mAb (n = 5 per group) as described in Figure 4C . Mice were euthanized at day 18. The absolute numbers of CD45+, CD8+ and CD4+ cells per mg of tumor tissues (e), as well as the activation or functional phenotypes of CD8+ or CD4 tumor-infiltrating T cells (f) are shown. Data are presented as the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 by Student's t test. Table S3 ) of 56 NSCLC patients and 29 healthy donors tested by FGL1 specific ELISA. (E) Plasma FGL1 levels in cohort #3 NSCLC patients grouped by the status of metastasis or liver injury (as indicated by plasma ALT levels). Data are presented as the mean ± SEM. **p < 0.01; ***p < 0.001; NS, not significant by Student's t test. Survival analysis was conducted by Log-rank test.
